Drug Profile
Erlotinib companion diagnostic - Roche Diagnostics
Alternative Names: cobas EGFR Mutation Test v2; cobasEGFR Mutation TestLatest Information Update: 03 Jun 2016
Price :
$50
*
At a glance
- Originator Roche Diagnostics
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer
Most Recent Events
- 01 Jun 2016 US FDA approves Erlotinib companion diagnostic for use with plasma samples for Non-small cell lung cancer (Diagnosis) in USA
- 13 Nov 2015 The US FDA approves cobas® EGFR Mutation Test v2 for use with tumours samples for Non-small cell lung cancer (diagnosis) in USA
- 14 May 2013 Registered for Non-small cell lung cancer (diagnosis) in USA